The announcement that Panama will begin in mid-August the phase one study of a ribonucleic acid vaccine against Covid-19, developed by a biotechnology company in Germany, has generated great expectation on Tuesday.
On an interview with Radar television program, Dr. Eduardo Ortega-Barria, responsible for medical affairs of the Covid-19 Vaccine Research Consortium in the country, assured that this will only happen after the vaccine is approved by the General Directorate of Health, the Bioethics Committee and regulatory authorities in Panama.
Ortega-Barria stated that once the phase one is completed, phase two of clinical trials will be activated in September, where the safety of the vaccine candidate and his immune response will be assessed.
Those tests will be performed at the Institute for Scientific Research and High Technology Services of Panama. This institute was chosen as a reference center to carry out these laboratory tests in collaboration with the biotechnology and pharmaceutical companies, the doctor said. About the issue, the infectologist indicated that WHO established that in the first stage, the Covid-19 vaccine will be given to health workers, who represent about 1% of the world population, adults aged 65 years (8%) and people with some kind of disease (15%).
Source: Prensa Latina
Stay Safe!!
About the Author
